These outcomes mainly included the tumor response rate (e.g., objective response rate, disease control rate), quality of life (e.g., Karnofsky performance status), survival rate (e.g., 1-year, 2-years survival rate), immune function (e.g., CD3+, CD4+/CD8+ ratio), and tumor pain relief, among others. This evidence concerns the gene CD8A and neoplasm.